GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » EBITDA Margin %

ZYUS Life Sciences (TSXV:ZYUS) EBITDA Margin % : -3,322.88% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ZYUS Life Sciences's EBITDA for the three months ended in Jun. 2024 was C$-3.92 Mil. ZYUS Life Sciences's Revenue for the three months ended in Jun. 2024 was C$0.12 Mil. Therefore, ZYUS Life Sciences's EBITDA margin for the quarter that ended in Jun. 2024 was -3,322.88%.


ZYUS Life Sciences EBITDA Margin % Historical Data

The historical data trend for ZYUS Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences EBITDA Margin % Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
EBITDA Margin %
-8,236.71 -5,176.85 -11,983.19

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -9,542.86 -3,267.68 -30,152.58 -2,148.25 -3,322.88

Competitive Comparison of ZYUS Life Sciences's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's EBITDA Margin % falls into.



ZYUS Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ZYUS Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-42.061/0.351
=-11,983.19 %

ZYUS Life Sciences's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-3.921/0.118
=-3,322.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences  (TSXV:ZYUS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ZYUS Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ZYUS Life Sciences Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences Headlines

No Headlines